LASA vs SUNPHARMA: Stock Comparison

Lasa Supergenerics Limited vs Sun Pharmaceutical Industries Ltd

Live data: 22 July 2026, 2:37 PM IST • Source: NSE and company filings

Sun Pharmaceutical Industries Ltd is the larger company by market capitalisation. Sun Pharmaceutical Industries Ltd shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Lasa Supergenerics Limited and Sun Pharmaceutical Industries Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, LASA is more favourable on 0 of 11 scored metrics and SUNPHARMA on 11These counts are context-free and are not an overall rating.

Key Differences

Market Cap
SUNPHARMA is the larger company
₹4.66 L Cr vs ₹36 Cr
EPS
SUNPHARMA has higher earnings per share
₹47.87 vs ₹-6.8
Dividend Yield
SUNPHARMA has a higher dividend yield
0.82% vs 0%
Revenue Growth (TTM YoY)
SUNPHARMA has faster revenue growth
12.8% vs 0%
EPS Growth (TTM YoY)
SUNPHARMA has faster EPS growth
25.6% vs 0%
Qtr Sales Growth
SUNPHARMA has stronger quarterly sales growth
12.8% vs -100%
Qtr Profit Growth
SUNPHARMA has stronger quarterly profit growth
13.6% vs -139%
ROE
SUNPHARMA has a higher ROE
16% vs -19.6%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricLASASUNPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricLASASUNPHARMA
Live Price₹7.21₹1,940
Day Change-1.23%-1.12%
Volume4,64413.17 L
52-Week High₹14.08₹1,966.5
52-Week Low₹5.67₹1,548
Distance from 52W High-48.79%-1.35%

Valuation

MetricLASASUNPHARMA
Market Cap₹36 Cr₹4.66 L Cr
P/E Ratio41.01x
P/B Ratio5.63x
EPS₹-6.8₹47.87
Book Value₹9.89₹348.31
Dividend Yield0%0.82%

Growth

MetricLASASUNPHARMA
Revenue Growth (TTM YoY)0%12.8%
EPS Growth (TTM YoY)0%25.6%
Qtr Sales Growth-100%12.8%
Qtr Profit Growth-139%13.6%

Profitability & Leverage

MetricLASASUNPHARMA
ROE-19.6%16%
ROCE-18.2%20.5%
Net Margin-135.6%18.56%
Operating Margin-29.3%28.2%
Debt to Equity0.2x0.06x

Shareholding

As of Mar 2026 • change vs previous quarter
MetricLASASUNPHARMA
Promoter Holding53.65%54.48%
FII Holding0%14.53% 1.4 pp
DII Holding0%22.18% 1.07 pp
Public Holding46.35%8.81% 0.33 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Lasa Supergenerics Limited and Sun Pharmaceutical Industries Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.